Episode Details
Back to Episodes
Cannabis Industry Pivots to Medical: Schedule III, FDA Trials, and Investment Opportunities
Published 1 month, 2 weeks ago
Description
In the past 48 hours, the cannabis industry shows a strong pivot toward medical and pharmaceutical applications, driven by recent U.S. federal shifts like President Trumps executive order moving cannabis to Schedule III, easing research barriers and eliminating punitive Section 280E taxes[3][5]. This has sparked strategic announcements from leaders: Aurora Cannabis is focusing solely on global medical markets, as highlighted at the TD Cowen Healthcare Conference, while Tilray Brands launched Tilray Medical USA to tap federally regulated medicine[3]. MMJ International Holdings, ahead of the curve, has spent a decade in FDA trials, completing pharmaceutical-grade formulations and clinical groundwork that peers are just starting, taking 8 to 12 years typically[3].
Market movements reflect optimism: On March 8, Tilray Brands (TLRY), Canopy Growth (CGC), and Cronos Group (CRON) led trading volume among cannabis stocks, signaling investor focus[4]. High-yield REITs like NewLake Capital Partners (NLCP) offer an 11.1 percent dividend yield, trading at a discount, poised for tenant profitability boosts from rescheduling[5]. No major deals, product launches, or disruptions emerged in the last 48 hours, but South Africas 14 billion rand sector advances regulatory overhaul for formalization[6].
Compared to prior weeks, this builds on February momentum without new volatility; stocks watched last week were similar, but medical emphasis intensified post-Schedule III[3][4]. Consumer behavior shifts toward clinically validated products, with no verified price or supply chain data from the past week. Leaders like Aurora and Tilray respond by reallocating to pharma, positioning for multibillion-dollar regulated medicine over retail[3]. Overall, the industry matures amid regulatory tailwinds, favoring early compliers. (298 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Market movements reflect optimism: On March 8, Tilray Brands (TLRY), Canopy Growth (CGC), and Cronos Group (CRON) led trading volume among cannabis stocks, signaling investor focus[4]. High-yield REITs like NewLake Capital Partners (NLCP) offer an 11.1 percent dividend yield, trading at a discount, poised for tenant profitability boosts from rescheduling[5]. No major deals, product launches, or disruptions emerged in the last 48 hours, but South Africas 14 billion rand sector advances regulatory overhaul for formalization[6].
Compared to prior weeks, this builds on February momentum without new volatility; stocks watched last week were similar, but medical emphasis intensified post-Schedule III[3][4]. Consumer behavior shifts toward clinically validated products, with no verified price or supply chain data from the past week. Leaders like Aurora and Tilray respond by reallocating to pharma, positioning for multibillion-dollar regulated medicine over retail[3]. Overall, the industry matures amid regulatory tailwinds, favoring early compliers. (298 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI